To see the other types of publications on this topic, follow the link: Oral Anxiety Disorders.
Journal articles on the topic 'Oral Anxiety Disorders'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Oral Anxiety Disorders.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Simpson, Carra A., Orli S. Schwartz, Djamila Eliby, Catherine A. Butler, Katherine Huang, Neil O'Brien-Simpson, Bridget L. Callaghan, et al. "Bugs and Brains, the Gut and Mental Health Study: a mixed-methods study investigating microbiota composition and function in anxiety, depression and irritable bowel syndrome." BMJ Open 11, no. 3 (March 2021): e043221. http://dx.doi.org/10.1136/bmjopen-2020-043221.
Full textAbstract:
IntroductionResearch has highlighted relationships between the micro-organisms that inhabit our gastrointestinal tract (oral and gut microbiota) with host mood and gastrointestinal functioning. Mental health disorders and functional gastrointestinal disorders co-occur at high rates, although the mechanisms underlying these associations remain unclear. The Bugs and Brains Study aims to investigate complex relationships between anxiety/depression and irritable bowel syndrome (IBS) in two ways. First, its primary component will compare the gut and oral microbiota in females with anxiety/depression and/or IBS relative to controls, and investigate underlying physiological, endocrine and immune factors, as well as associations with diet and psychosocial factors. In an ancillary component, the study will also investigate gastrointestinal and mental health symptoms in a larger sample, and explore relationships with diet, exercise, oral health, substance use, medical history, early life adversity and psychosocial factors.Methods and analysisThe Bugs and Brains Study aims to recruit 160 females to the primary component: (1) 40 controls; (2) 40 participants with a depressive/anxiety disorder, but no IBS; (3) 40 participants with IBS, but no depressive/anxiety disorder and (4) 40 participants with both depressive/anxiety disorder and IBS. Participation is completed within 1 month, and involves comprehensive questionnaires, anthropometrics, a diagnostic clinical interview, collection of two saliva samples, and stool, urine and hair samples. This study aims to use a systems biology approach to characterise oral and gut microbial composition and function using 16S rRNA gene sequencing and nuclear MR spectroscopy. As part of the ancillary component, it will collect questionnaire data from 1000 participants aged 18–40 years, capturing mental health, gastrointestinal health, oral health, diet and psychosocial factors.Ethics and disseminationApproval was granted by the University of Melbourne Human Research Ethics Committee (#1749221). All participants voluntarily provided informed consent. Results will be published in peer-reviewed journals and presented at scientific conferences.
2
Gualtieri, P., M. Marchetti, G. Cioccoloni, A. De Lorenzo, L. Romano, A. Cammarano, C. Colica, R. Condò, and L. Di Renzo. "Psychobiotics Regulate the Anxiety Symptoms in Carriers of Allele A of IL-1β Gene: A Randomized, Placebo-Controlled Clinical Trial." Mediators of Inflammation 2020 (January 7, 2020): 1–11. http://dx.doi.org/10.1155/2020/2346126.
Full textAbstract:
Background. Probiotic oral intake, via modulation of the microbiota-gut-brain axis, can impact brain activity, mood, and behavior; therefore, it may be beneficial against psychological distress and anxiety disorders. Inflammatory cytokines can influence the onset and progression of several neurodegenerative mood disorders, and the IL-1β rs16944 SNP is related to high cytokine levels and potentially affects mood disorders. The aim of this study was to examine the combined effect of IL-1β polymorphism and probiotic administration in mood disorder phenotypes in the Italian population. Methods. 150 subjects were randomized into two different groups, probiotic oral suspension group (POSG) and placebo control group (PCG), and received the relative treatment for 12 weeks. Psychological profile assessment by Hamilton Anxiety Rating Scale (HAM-A), Body Uneasiness Test (BUT), and Symptom Checklist 90-Revised (SCL90R) was administered to all volunteers. Genotyping was performed on DNA extracted from salivary samples. Results. After 12 weeks of intervention, a significant reduction of HAM-A total score was detected in the POSG (p<0.01), compared to the PCG. Furthermore, IL-1β carriers have moderate risk to develop anxiety (OR=5.90), and in POSG IL-1β carriers, we observed a reduction of HAM-A score (p=0.02). Conclusions. Consumption of probiotics mitigates anxiety symptoms, especially in healthy adults with the minor A allele of rs16944 as a risk factor. Our results encourage the use of probiotics in anxiety disorders and suggest genetic association studies for psychobiotic-personalized therapy.
3
Токмакова, С., S. Tokmakova, О. Бондаренко, O. Bondarenko, О. Сысоева, O. Sisoeva, К. Шестун, and K. Shestun. "CORRECTION OF ANXIETY DISORDE RS IN THE COMPLEX TREATMENT OF OR ALMUCOUSDISEASES." Actual problems in dentistry 9, no. 1 (February 25, 2013): 20–22. http://dx.doi.org/10.18481/2077-7566-2013-0-1-20-22.
Full textAbstract:
<p> Most of the diseases mucous membranes of the mouth occur against a background of disorders of the nervous system. Anxiety disorders can complicate the course of dental pathology. For the assessment of anxiety and depression survey patients were conducted by scale hospital anxiety and depression hads. The studies allowed us to describe the patients with oral mucous diseases as suffering from anxiety disorders. To reduce the symptoms of anxiety disorders and timely correction of identified violations of all patients was appointed anksiolitic, on a background of reception of which the questionnaire noted significant decrease of the level of alarm and depression.</p><p> </p>
4
Maksimova, M. Yu, S. N. Illarioshkin, and N. A. Sineva. "Burning mouth syndrome in menopausal women." Russian neurological journal 26, no. 4 (August 12, 2021): 39–45. http://dx.doi.org/10.30629/2658-7947-2021-26-4-39-45.
Full textAbstract:
Many women in menopause experience discomfort in the oral cavity — burning, dysesthesia, xerostomia, taste changes, which lead to a reduction in the quality of life.Aim: to identify clinical and psychological factors associated with the development of burning mouth syndrome in menopausal women.Material and methods. Were examined 67 women aged 45–67 years. Assessment of oral pain performed using the Visual analog scale (VAS). Assessment of dry mouth symptoms severity performed using the Challacombe Scale of Clinical Oral Dryness (CSCOD). Psychometric tests was carried out with Spielberger’s Anxiety Test, Montgomery–Asberg Depression Rating Scale (MADRS), Hospital Anxiety and Depression Scale (HADS), Mini-Mental State Examination (MMSE). The Psychological stress measure-25 scale was also used to assess the impact of stress on somatic, behavioral, and emotional indicators of life. The quality of life was measured using the Oral Health Impact Profile-14 (OHIP-14).Results. Clinically, burning mouth syndrome in menopausal women manifested with various oral symptoms include paresthesias and pain in the tongue, oral cavity, as well as xerostomia and taste disorders. Painful sensations in the tongue developed 1–3 years after the menopause onset and was preceded by stressful life events. The pain scores on the VAS was 63.1 ± 11.8 mm. Depressive disorders were characterized by an average level of personal and situational anxiety, instability to stressful influences. The quality of life assessment in menopausal women using the OHIP-14 scale, the total score was 17.1 ± 5.21 points and corresponded to the sufficient quality of oral health.Conclusion. Burning mouth syndrome and neuropsychiatric disorders (anxiety, asthenia, depression, phobia, sleep disorders) in menopausal women are pathophysiologically related conditions.
5
Sahni, Vaibhav. "Psychological Impact of Facial Trauma." Craniomaxillofacial Trauma & Reconstruction 11, no. 1 (March 2018): 015–20. http://dx.doi.org/10.1055/s-0037-1603464.
Full textAbstract:
Examination of the mental state of patients suffering from facial trauma is rarely ever recorded, let alone screening them for posttraumatic stress disorders (PTSDs) or generalized anxiety disorder. Providing early support to the patient in light of such psychological conditions can improve the overall quality of life. The aim of this study was to perform a literature review to assess the relation of mental state disorders to facial trauma in terms of their prevalence, assess screening methodology, and also to evaluate the prognosis of individuals subjected to psychological intervention/screening at an early stage of clinical examination. Research databases such as ScienceDirect, Google Scholar, PubMed, and Medline were searched using the keywords “psychological trauma,” “facial trauma,” and “PTSD.” Only meta-analyses, systematic reviews, and original research articles in the English language were included in the study. Correspondence to journal editors and clinician opinions were excluded from the study. Out of a total of 459 results, only 8 articles satisfied the inclusion criteria of the study. The literature review showed that patients suffering from orofacial trauma had significantly increased levels of mental state disorders such as PTSD and generalized anxiety disorder, more so in victims of assault. The results of this literature review clearly point toward an increased prevalence of mental state disorders in patients suffering from facial trauma, which warrants for early intervention in this regard to improve the quality of life of these patients.
6
Freret, Thomas, Stacy Largilliere, Gerald Nee, Melanie Coolzaet, Sophie Corvaisier, and Michel Boulouard. "Fast Anxiolytic-Like Effect Observed in the Rat Conditioned Defensive Burying Test, after a Single Oral Dose of Natural Protein Extract Products." Nutrients 13, no. 7 (July 17, 2021): 2445. http://dx.doi.org/10.3390/nu13072445.
Full textAbstract:
Anxiety appears among the most frequent psychiatric disorders. During recent years, a growing incidence of anxiety disorders can be attributed, at least in part, to the modification of our eating habits. To treat anxiety disorders, clinicians use benzodiazepines, which unfortunately display many side effects. Herein, the anxiolytic-like properties of two natural products (αS1–casein hydrolysate and Gabolysat®) were investigated in rats and compared to the efficacy of benzodiazepine (diazepam). Thus, the conditioned defensive burying test was performed after a unique oral dose of 15 mg/kg, at two time-points (60 min and then 30 min post oral gavage) to show potential fast-onset of anxiolytic effect. Both natural products proved to be as efficient as diazepam to reduce the time rats spent burying the probe (anxiety level). Additionally, when investigated as early as 30 min post oral gavage, Gabolysat® also revealed a fast-anxiolytic activity. To date, identification of bioactive peptide, as well as how they interact with the gut–brain axis to sustain such anxiolytic effect, still remains poorly understood. Regardless, this observational investigation argues for the consideration of natural compounds in care pathway.
7
Lopez-Yufera, Elia, Pia López-Jornet, Oscar Toralla, and Eduardo Pons-Fuster López. "Non-Pharmacological Interventions for Reducing Anxiety in Patients with Potentially Malignant Oral Disorders." Journal of Clinical Medicine 9, no. 3 (February 26, 2020): 622. http://dx.doi.org/10.3390/jcm9030622.
Full textAbstract:
Objective: To evaluate the effect of a music intervention upon anxiety, blood pressure, and heart rate in adult patients with potentially malignant oral disorders. Methods: Eighty consecutive adults (mean age: 68.3 years) consulting a Unit of Oral Medicine (Murcia Spain) were randomized to a study group (n = 40) that listened to music through headphones during 10 min or to a control group (n = 40). Corah’s dental anxiety score, blood pressure, heart rate, oxygen saturation (oximetry), skin temperature, and salivation were recorded at different timepoints before and after patient consultation. Results: Significant pre- versus post-consultation reductions were observed in blood pressure (p < 0.001) and heart rate (p < 0.001), though not in temperature, salivation, and oxygen saturation (p > 0.05). There were no significant differences between the study group and the controls (p > 0.05). Conclusions: The applied music intervention had no apparent effect upon anxiety. Further studies using different music intervention strategies and/or analytic parameters are needed to explore the benefits of this approach to decreasing anxiety.
8
De Stefano, Rosa, Antonio Bruno, Maria Rosaria Anna Muscatello, Clemente Cedro, Alessandra Cicciù, Rosario Rullo, Michele Gaeta, and Luca Fiorillo. "Oral Health and Fibromyalgia Syndrome: A Systemic Review." Journal of Functional Morphology and Kinesiology 5, no. 1 (January 25, 2020): 7. http://dx.doi.org/10.3390/jfmk5010007.
Full textAbstract:
Fibromyalgia is a syndrome currently considered idiopathic and multifactorial rheumatic that causes an increase in muscle tension and is characterized by muscle pain and chronic fibrous tissues—widespread, fluctuating and migrating—associated with stiffness, asthenia, cognitive disorders, insomnia or sleep disorders, alterations in sensitivity to stimuli. In affected patients, there may be anxiety or depressive disorder development. The aim of this study is, with the help of an interdisciplinary team, to evaluate the correlations between this syndrome and oral health. A literature review was conducted, analyzing the most common scientific databases, more than 200 studies were obtained. Subsequently to the application of filters and revision by the authors, only 18 articles were considered eligible for this review. From the results, it is clear that the correlations between fibromyalgia and oral health mainly concern pain in the oro-maxillofacial district, especially in the temporomandibular joint. This certainly could help for faster diagnosis of the syndrome, which is currently difficult to identify.
9
Velleman, Shelley L., and Carolyn B. Mervis. "Children With 7q11.23 Duplication Syndrome: Speech, Language, Cognitive, and Behavioral Characteristics and Their Implications for Intervention." Perspectives on Language Learning and Education 18, no. 3 (October 2011): 108–16. http://dx.doi.org/10.1044/lle18.3.108.
Full textAbstract:
7q11.23 duplication syndrome is a recently documented genetic disorder associated with severe speech delay, language delay, a characteristic facies, hypotonia, developmental delay, and social anxiety. Children with this syndrome demonstrate developmentally appropriate nonverbal pragmatic abilities in socially comfortable situations. Motor speech disorder (childhood apraxia of speech and/or dysarthria), oral apraxia, and/or phonological disorder, or symptoms of these disorders, are common, as are characteristics consistent with expressive language disorder. Intensive speech/language therapy is critical for maximizing long-term outcomes.
10
Cosci, Fiammetta, Koen Schruers, Carlo Faravelli, and Eric Griez. "The influence of alcohol oral intake on the effects of 35% CO2 challenge. A study in healthy volunteers." Acta Neuropsychiatrica 16, no. 2 (April 2004): 107–9. http://dx.doi.org/10.1111/j.0924-2708.2004.0077.x.
Full textAbstract:
Objective:Alcohol use disorders and panic disorder co-occur at a rate that exceeds chance significantly. The underlying mechanism of alcoholism associated with anxiety has rarely been examined using experimental methodologies. The present study in healthy volunteers tested whether alcohol consumption reduces anxiety associated with a panic-challenge procedure (35% CO2 challenge).Methods:The study design was placebo-controlled, double-blind, randomized. Eight healthy volunteers were enrolled; all subjects had an alcohol and a placebo oral intake according to a crossover design. After each consumption the subjects underwent the 35% CO2 challenge and a series of anxiety symptom assessments.Results:After the alcohol intake, the subjects presented a significant reduction in the anxiety state associated with the challenge procedure. The Panic Symptom List score is significantly lower after alcohol intake (P = 0.032), as compared with the placebo, and the Visual Analogue Anxiety Scale shows a trend to be lower after alcohol intake (P = 0.111).Conclusions:Moderate doses of alcohol acutely decrease the response to a 35% CO2 challenge in healthy volunteers. These results lend support to the pharmacological anxiolytic effect of alcohol and suggest that this property may reinforce the drinking behaviour among those with high levels of anxiety.
11
Kamilly Leitão Pitman Machado, Adriana, Caio Vinicius Botelho Brito, João Augusto Gomes de Souza Monteiro de Brito, Carla Andrea Avelar Pires, and Francisca Regina Oliveira Carneiro. "Evaluation of Depression and Anxiety Disorders and Correlation with the Treatment of Patients with Psoriasis Vulgaris." Journal of the Portuguese Society of Dermatology and Venereology 78, no. 4 (December 19, 2020): 321–27. http://dx.doi.org/10.29021/spdv.78.4.1224.
Full textAbstract:
Introduction: Psoriasis is a chronic inflammatory multisystemic disease with several comorbidities, namely anxiety and depression disorders.
Methods: In this study, the prevalence of these psychiatric entities was investigated by the PHQ-9 and GAD-7 questionnaries and related to the socio-demographic variables and to the forms of clinical treatment.
Results: A total of 90 patients (56 females) were analyzed. Of these, 41 patients (45.56%) used topical treatment only, 28 patients (31.11%) used oral methotrexate and 21 patients (23.33%) used immunobiological agents (anti-TNF-alfa agents). It was observed that 47 patients (52.23%) presented some degree of depression (mild, moderate or severe) and 53 patients (58.89%) presented some degree of anxiety disorder (mild, moderate or severe). There was no statistical relationship between the anxiety and depression scores and the PASI score, as well as age, employability or schooling. There was a statistical association between psychiatric comorbidities and the female gender (p <0.0001). It was also observed a lower prevalence of depression (p = 0.0336) on patients using immunobiological treatments.
Conclusion: The findings confirm published data, showing association of psychiatric conditions with psoriasis, especially in relation to TNF-alpha, so that anti-TNF therapies may become an alternative for the treatment of depression or anxiety disorders associated with psoriasis.
12
Laird, Stephanie, Luke J. Ney, Kim L. Felmingham, and Andrea Gogos. "Hormonal Contraception and the Brain: Examining Cognition and Psychiatric Disorders." Current Psychiatry Research and Reviews 15, no. 2 (September 13, 2019): 116–31. http://dx.doi.org/10.2174/1573400515666190521113841.
Full textAbstract:
Background: The combined oral contraceptive pill (OC), containing synthetic estrogens and progestins, is used by millions of women worldwide, yet little is known about its effects on cognition or on psychiatric disorders. The progestin component of OCs determines their androgenicity, i.e. whether the OC has androgen binding components with masculinising effects or antiandrogenic components with feminising effects. Objective: The present review discusses the literature surrounding OC use and cognition in healthy women. Given the important role that sex hormones play in psychiatric disorders, we also consider the influence of OCs on symptoms of schizophrenia, post-traumatic stress disorder, depression, bipolar disorder, anxiety disorders and indirectly, sleep quality. Results: Research has shown that while there are no differences between OC users and non-users, androgenic OCs enhance visuospatial ability and anti-androgenic OCs enhance verbal fluency. Little is known about OCs effects on other cognitive domains, such as memory and executive function. There is little research examining OC use in schizophrenia, post-traumatic stress disorder, bipolar disorder and anxiety disorders. There is some evidence that OC use is associated with depression, however the exact causality of this association remains to be verified. Conclusion: We maintain that future studies need to address several methodological limitations, such as separating OCs based on androgenicity to avoid the masking effects that occur when various OCs are considered as one group. As this review highlights several significant effects of OC use on the brain, the implications of OC use needs to be considered in future research.
13
Baig, Arfa, Bushra Ghani, Oam Parkash, Lubna Memon, Shoaib Muhammad Chohan, and Daud Sultan. "“Evaluation of frequency of anxiety and depression among patients with chronic temporomandibular disorder.”." Professional Medical Journal 26, no. 10 (October 10, 2019): 1724–32. http://dx.doi.org/10.29309/tpmj/2019.26.10.3709.
Full textAbstract:
Temporomandibular Disorder (TMD) has been considered as one of the commonest disorder in Pakistan. In this disorder, the patient complains of pain in Temporomandibular joint and associated anatomical muscles. This research study has been performed to evaluate the frequency of Anxiety and Depression in patients with Chronic Temporomandibular Disorder (CTMD). Objectives: The objective of this research study is to evaluate the frequency of Anxiety and Depression among patients with Chronic Temporomandibular joint Disorder. Study Design: A Cross-sectional Descriptive research study. Setting: This research study was conducted in the Department of Oral and Maxillofacial Surgery at Dr. Ishrat-ul-Ebad Khan Institute of Oral and Health sciences, Dow University of Health Sciences and Dr. Ruth K.M. Pfau Civil Hospital, Karachi, Pakistan. Period: This research study was conducted for a respective period of 1 year from 1st March 2018 to 1st March 2019. Materials and Methods: A total of 213 patients having persisting Temporomandibular joint pain for more than 6 months were included in this study. The diagnosis of Temporomandibular Disorder (TMD) was established if the patient demonstrated pain/discomfort in the Temporomandibular Joint (TMJ) and muscles of mastication and masticatory dysfunction for a period, exceeding 6 months. After demographic questions, Hospital Anxiety and Depression Scale (HADS) was administered to each patient and the intensity and severity of Anxiety and Depression were recorded and documented by the Operator. Results: The percentage of Anxiety and Depression among patients with Chronic Temporomandibular Disorder (TMD) was 31.46% (67/213) and 36.15% (77/213). Conclusion: In our respective study, the Frequency of psychological disorders like Anxiety and Depression were significantly high. Our results showed that an adequate and profound diagnosis and treatment planning is very necessary for all patients suffering from Chronic Temporomandibular Disorder (CTMD) so that both physical and psychological factors of patients with Chronic Temporomandibular Disorder (CTMD) should be taken into primary foremost consideration prior to the decision pertaining to its management respectively.
14
Vigna, Luisella, Federica Morelli, Gianna M. Agnelli, Filomena Napolitano, Daniela Ratto, Alessandra Occhinegro, Carmine Di Iorio, et al. "Hericium erinaceus Improves Mood and Sleep Disorders in Patients Affected by Overweight or Obesity: Could Circulating Pro-BDNF and BDNF Be Potential Biomarkers?" Evidence-Based Complementary and Alternative Medicine 2019 (April 18, 2019): 1–12. http://dx.doi.org/10.1155/2019/7861297.
Full textAbstract:
Epidemiological data indicate that subjects affected by obesity have an increased risk of developing mood disorders. The relationship between obesity and mood disorders is bidirectional. We assessed whether a Hericium erinaceus treatment improved depression, anxiety, sleep, and binge eating disorders after 8 weeks of supplementation in subjects affected by overweight or obesity under a low calorie diet regimen. Looking for a possible clinical biomarker, we assessed the serum balance between brain-derived neurotrophic factor (BDNF) and its precursor pro-BDNF before and after H. erinaceus supplementation. Seventy-seven volunteers affected by overweight or obesity were recruited at the offices of the Department of Preventive Medicine, Luigi Devoto Clinic of Work, Obesity Centre, at the IRCCS Foundation Policlinico Hospital of Milan (Italy). Patients were recruited only if they had a mood and/or sleep disorder and/or were binge eating as evaluated through self-assessment questionnaires. We used two different enzyme-linked immunosorbent assays kits to discriminate circulating levels of pro-BDNF and BDNF. Eight weeks of oral H. erinaceus supplementation decreased depression, anxiety, and sleep disorders. H. erinaceus supplementation improved mood disorders of a depressive-anxious nature and the quality of the nocturnal rest. H. erinaceus increased circulating pro-BDNF levels without any significant change in BDNF circulating levels.
15
Spector, Anna M., Teodor T. Postolache, Faisal Akram, Alison J. Scott, Abhishek Wadhawan, and Mark A. Reynolds. "Psychological Stress: A Predisposing and Exacerbating Factor in Periodontitis." Current Oral Health Reports 7, no. 3 (August 11, 2020): 208–15. http://dx.doi.org/10.1007/s40496-020-00282-2.
Full textAbstract:
Abstract Purpose of Review This review focuses on recent advances in our understanding of the interactions between psychological stress, the immune system, and periodontitis, including the dynamic role of host stress responses in altering immune function, altering the oral microbiome and biofilm formation, and promoting local and systemic disease progression. Recent Findings Within the context of periodontal health and disease, stress leads to an impairment of effective antimicrobial defense, shifts in oral microbiome profiles toward more pathogenic gene expression and taxa composition, increased translocation, and biofilm formation. The link between stress and periodontitis is multiform and includes hypothalamic–pituitary–adrenal (HPA) axis and catecholamine activation, production of immune mediators of inflammation and, clinically, syndromes of depression, bipolar disorder, anxiety disorders, and sleep-wake disorders. Summary Psychological stress appears to be an important modifiable risk factor for the development and progression of periodontitis and other periodontal diseases.
16
Cardoso, Juliana Andrade, André Avelino dos Santos Junior, Maria Lucia Tiellet Nunes, Maria Antonia Zancanaro de Figueiredo, Karen Cherubini, and Fernanda Gonçalves Salum. "Salivary Alpha-Amylase Enzyme, Psychological Disorders, and Life Quality in Patients with Recurrent Aphthous Stomatitis." International Journal of Dentistry 2017 (2017): 1–6. http://dx.doi.org/10.1155/2017/5269856.
Full textAbstract:
Objective. The aim of this study was to evaluate stress, anxiety, and salivary alpha-amylase (SAA) activity in patients with recurrent aphthous stomatitis (RAS). The impact of this disease on the life quality was also evaluated.Design. Twenty-two patients with RAS and controls, matched by sex and age, were selected. Stress and anxiety were assessed using Lipp’s Inventory of Stress Symptoms and Beck Anxiety Inventory. Life quality was assessed through the World Health Organization Quality of Life-bref (WHOQOL-BREF) and the Oral Health Impact Profile-14 (OHIP-14). Saliva samples were collected in the morning and afternoon and the SAA activity was analyzed by enzymatic kinetic method.Results. No significant difference was observed between the groups regarding the SAA activity (p=0.306). Patients with RAS had higher scores of anxiety (p=0.016). The scores of WHOQOL-BREF were significantly lower in patients with RAS. The values obtained through OHIP-14 were significantly higher in these patients (p=0.002).Conclusion. RAS negatively affects the life quality. Patients with the disease have higher levels of anxiety, suggesting its association with the etiopathogenesis of RAS.
17
Gasparro, Roberta, Elena Calabria, Noemi Coppola, Gaetano Marenzi, Gilberto Sammartino, Massimo Aria, Michele Davide Mignogna, and Daniela Adamo. "Sleep Disorders and Psychological Profile in Oral Cancer Survivors: A Case-Control Clinical Study." Cancers 13, no. 8 (April 13, 2021): 1855. http://dx.doi.org/10.3390/cancers13081855.
Full textAbstract:
Quality of sleep (QoS) and mood may impair oral cancer survivors’ wellbeing, however few evidences are currently available. Therefore, we aimed to assess the prevalence of sleep disorders, anxiety and depression among five-year oral cancer survivors (OC survivors). 50 OC survivors were compared with 50 healthy subjects matched for age and sex. The Pittsburgh Sleep Quality Index (PSQI), the Epworth Sleepiness Scale (ESS), the Hamilton Rating Scales for Depression and Anxiety (HAM-D, HAM-A), the Numeric Rating Scale (NRS), the Total Pain Rating Index (T-PRI) were administered. The global score of the PSQI, ESS, HAM-A, HAM-D, NRS, T-PRI, was statistically higher in the OC survivors than the controls (p-value: <0.001). QoS of OC survivors was significantly impaired, especially with regard to some PSQI sub-items as the subjective sleep quality, sleep latency and daytime dysfunction (p-value: 0.001, 0.029, 0.004). Moreover, poor QoS was negatively correlated with years of education (p-value: 0.042 *) and positively correlated with alcohol consumption (p-value: 0.049 *) and with the use of systemic medications (p-value: 0.044 *). Sleep disorders and mood disorders are common comorbidities in OC survivors; therefore, early assessment and management before, during and after treatment should be performed in order to improve the quality of life of OC survivors.
18
Tapilskaya, Natalya I., Mikhail S. Nekrasov, Inna O. Krikheli, Ksenia V. Ob'edkova, Alexander M. Gzgzyan, Igor Y. Kogan, and Ruslan I. Glushakov. "Stress-protective effects of micronized progesterone in treatment of anxiety disorders in pregnant women after in vitro fertilisation." Gynecology 23, no. 4 (September 22, 2021): 346–53. http://dx.doi.org/10.26442/20795696.2021.4.201091.
Full textAbstract:
Aim. To study a stress-protective efficacy of micronized progesterone (MP) in pregnant women with anxiety disorders after in vitro fertilisation (IVF).
Materials and methods. We conducted a prospective, comparative open-label randomized trial in two IVF-clinics. A total of 98 pregnant women after IVF with anxiety disorders were recruited at the 9th week of pregnancy. Progesterone supplementation after IVF for luteal phase support was administered out until 9 weeks gestation. Then, after randomization, group 1 (n=35) received 400 mg per day of MP vaginally, group 2 (n=33) received 400 mg of MP orally, group 3 (n=30) was comparative for the other groups. The duration of progesterone treatment was 12 weeks. The Spielberger State Trait Anxiety Inventory (STAI), the Montgomerysberg depression rating scale (MADRS), Hospital Anxiety and Depression Scale (HADS), and the Epworth Sleepiness Questionnaires (ESQ) were used to compare maternal mood at 9 weeks (day of randomization) after delivery and at 283, 565, 847 days after randomization.
Results. The mean STAI sumscore in MP-groups was significantly lower than in group 3 starting from day 565 and continued until the end of the study. There were no significant differences between vaginal and oral administration of progesterone. There were no significant differences between the mean sumscores when questioning on the HADS, MADRS and ESQ.
Conclusion. Prolonged use of MP in pregnant women with anxiety disorders led to the prevention of manifestations of an increase in anxiety and depression. The stress-protective and neuromodulating properties of MP can determine additional indications for its prolonged administration in women with anxiety disorders and/or premorbid history.
19
Addicks, S. H., D. W. McNeil, C. L. Randall, A. Goddard, L. M. Romito, C. Sirbu, G. Kaushal, A. Metzger, and B. D. Weaver. "Dental Care–Related Fear and Anxiety: Distress Tolerance as a Possible Mechanism." JDR Clinical & Translational Research 2, no. 3 (February 9, 2017): 304–11. http://dx.doi.org/10.1177/2380084417691962.
Full textAbstract:
Distress tolerance, the degree to which one is able to cope with and endure negative emotional states, has been broadly applied to understand and treat a variety of health (including behavioral) problems, but little is known about its role in oral health care and specifically dental care–related fear and anxiety, making it a novel construct in the oral health care literature. This cross-sectional study examined distress tolerance as a possible predictor of dental fear and anxiety among a sample of adults with and without diagnoses of dental phobia, investigated possible differences in levels of distress tolerance between adults with and without dental phobia, and determined possible associations between distress tolerance and fear of pain, anxiety sensitivity, and depression. Using 52 volunteers ( n = 31, dental phobia group; n = 21, healthy comparison group), this investigation used self-report measures of distress tolerance, fear of pain, anxiety sensitivity, dental fear, and depression. The Anxiety Disorders Interview Schedule, a semi-structured interview, was used to assess for dental phobia and other psychological disorders. Distress tolerance significantly predicted dental fear and anxiety, even after controlling for age, sex, fear of pain, anxiety sensitivity, and depression. In addition, the dental phobia group had lower distress tolerance than the healthy comparison group. Distress tolerance was significantly associated with fear of pain, anxiety sensitivity, and depression. Findings indicate that low distress tolerance plays a unique and distinct role as a possible mechanism in the genesis of dental care–related fear and anxiety and phobia and may exacerbate the experience of other states, including fear of pain and anxiety sensitivity. Knowledge Transfer Statement: Results indicate that patients who have a lower ability to tolerate emotional and physical distress may have higher levels of dental care–related fear and anxiety and even dental phobia, as well as associated sequelae (e.g., avoidance of dental care). Treatment of highly fearful dental patients may helpfully include a focus on increasing distress tolerance.
20
Romero-Cerecero, Ofelia, Ana Laura Islas-Garduño, Alejandro Zamilpa, Ma Dolores Pérez-García, and Jaime Tortoriello. "Therapeutic Effectiveness of Galphimia glauca in Young People with Social Anxiety Disorder: A Pilot Study." Evidence-Based Complementary and Alternative Medicine 2018 (September 27, 2018): 1–8. http://dx.doi.org/10.1155/2018/1716939.
Full textAbstract:
Social anxiety is one of the most common disorders found in the population attending the first level of health care. Galphimia glauca has been used for many years in Mexican traditional medicine to treat “nervous disorders”. A standardized extract of this species has been evaluated in clinical studies that have proven its efficacy and safety in patients with generalized anxiety disorder. In this work, a double-blind clinical trial was carried out, using sertraline as a control. Patients from both sexes (18 to 35 years old) with moderate or severe social anxiety were included. Experimental group was treated daily (orally), for 10 weeks, with an extract from G. glauca containing 0.374 mg/dose of Galphimine-B (G-B, active compound). Patients in the control group were given sertraline (50 mg) in the same conditions. All patients were evaluated every two weeks. Another assessment was done one month after the end of the administration period. A total of 34 patients was included, 17 in each group. Women were predominant, and the mean age was 25 ± 4.7 years. In patients who received the G. glauca standardized extract, a significant reduction in anxiety was observed, with a value (in the Brief Social Phobia Scale) of 41.1±10.3 points at the start and 11.2±5.6 points at the end of treatment, while patients treated with sertraline had a value of 37.7±7.3 points at the beginning and 11.1±5.2 points at the end. No significant difference was observed between the treated groups. In a similar way, the health scale showed a gradual and continuous improvement in each of the five evaluations. In conclusion, the 10-week oral administration of G. glauca standardized extract showed efficacy and safety in patients with social anxiety disorder, without showing a significant difference from patients treated with sertraline.
21
Loginova, K. B., G. M. Dyukova, Yu V. Dobrokhotova, and A. B. Danilov. "Treatment of premenstrual dysphoric disorders with combined oral contraceptives." Medical alphabet 2, no. 14 (December 2, 2019): 23–26. http://dx.doi.org/10.33667/2078-5631-2019-2-14(389)-23-26.
Full textAbstract:
Premenstrual dysphoric disorder (PMDD) is a severe form of premenstrual syndrome (PMS) with severe psycho-emotional disorders. The frequency of occurrence of PMDD in women of the reproductive period of the Russian Federation is estimated at an average of 15.6 %. The development of PMDD is based on the individual sensitivity of neurotransmitters and neuropeptides to fluctuations in the levels of sex steroid hormones of the ovulatory menstrual cycle, therefore, hormone therapy drugs are used for PMDD therapy — combined oral contraceptives (COC) that suppress ovulation.The purpose of this study was to evaluate the effectiveness of COC containing drospirenone in the treatment of PMDD.Materials and methods. 78 women of the reproductive period underwent a comprehensive examination and treatment of PMDD symptoms with contraceptives containing 30 mg of ethinyl estradiol and 3 mg of drospirenone (Midian).Results of the study. The age of patients with PMDD averaged 33.7 years; 55 % of women were between 25–34 years old; 97 % needed contraception; all women represented in the group had higher education, normal menstrual function and body mass index. After 3 months of treatment, there was a statistically significant decrease in pain of various localization, problems with appetite, difficulties in communicating with others, sleep disturbances, and an increase in productivity at work, at home and in school. After 6 months of treatment, COC psycho-emotional symptoms, such as depression, anger, irritation, emotional lability, anxiety, tension, loss of control, significantly regressed, while the effectiveness of therapy reached 50 % relative to the original background. Physical symptoms of PMS, such as swelling of the mammary glands, pain of various locations, sleep disturbances, were stopped on average by 70 %.Conclusions. COC containing drospirenone can be used to treat severe premenstrual syndrome, i. e. PMDD.
22
Caspersen, N., J. R. Hirsvang, L. Kroell, F. Jadidi, L. Baad-Hansen, P. Svensson, and R. Jensen. "Is There a Relation between Tension-Type Headache, Temporomandibular Disorders and Sleep?" Pain Research and Treatment 2013 (November 20, 2013): 1–6. http://dx.doi.org/10.1155/2013/845684.
Full textAbstract:
Introduction. Tension-Type Headache (TTH) is the most prevalent headache often associated with impaired function and quality of life. Temporomandibular Disorders (TMD) and TTH frequently coexist; characterized by pericranial tenderness and impact on daily life. We aim to apply a standardized questionnaire for TMD to characterize and analyse an eventual relation between sleep and oral health in TTH in a controlled design. Material and Methods. 58 consecutive TTH patients and 58 healthy controls were included. The Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD) questionnaire, Oral Health Impact profile (OHIP) and questionnaires for sleep were applied. Results. TTH-patients had significantly higher pain scores (), decreased quality of life (), and higher total sleep scores () compared to controls. Conclusion. For the first time we have identified a clear relation between TTH and TMD symptoms, depression, anxiety, poor sleep, and impairments of oral function in carefully classified patients. These findings indicate a close, but incomplete, overlap between TTH and TMD. Their underlying pathophysiological mechanisms need further research.
23
Glue, Paul, Natalie J. Medlicott, Shona Neehoff, Peter Surman, Fred Lam, Noelyn Hung, and Cheung-tak Hung. "Safety and efficacy of extended release ketamine tablets in patients with treatment-resistant depression and anxiety: open label pilot study." Therapeutic Advances in Psychopharmacology 10 (January 2020): 204512532092247. http://dx.doi.org/10.1177/2045125320922474.
Full textAbstract:
Background: Ketamine’s defining side effects are dissociation and increased blood pressure/heart rate. An oral formulation with delayed absorption could minimize these effects. We recently reported safety and tolerability data for an extended release ketamine tablet in healthy volunteers. Methods: To assess safety, tolerability, efficacy, and pharmacokinetics of an extended release oral ketamine tablet in patients with treatment-resistant depression/anxiety. This was a multiple dose open-label flexible dose uncontrolled study in seven patients with treatment-resistant depression/anxiety, who had all previously demonstrated mood improvement to subcutaneous ketamine. Assessments included ratings of anxiety, depression and dissociation, safety and tolerability, and blood samples for ketamine pharmacokinetics and brain-derived neurotrophic factor (BDNF) concentrations. Results: Improvements in anxiety and depression ratings occurred gradually over 96 h; all patients had >50% improvements in mood ratings. Ketamine was safe and well tolerated, with no changes in vital signs, and a single brief report of dissociation. Ketamine may induce its own metabolism, as the ratio of norketamine to ketamine increased out to 96 h. Serum BDNF concentrations did not change during the study. Conclusion: Ketamine’s safety/tolerability may be improved with an extended release oral formulation. Onset of mood improvement is slightly delayed compared with parenteral dosing. These data support the further development of extended release ketamine tablets for treatment of resistant depression and anxiety disorders.
24
Golovacheva, V. A., and G. R. Tabeeva. "Neurotic disorder, headache, and stress: experience of managing a comorbid patient and the role of magnesium drugs." Meditsinskiy sovet = Medical Council, no. 2 (March 22, 2021): 94–100. http://dx.doi.org/10.21518/2079-701x-2021-2-94-100.
Full textAbstract:
In the practice of neurologists and therapists, patients with complaints of headache, increased fatigue, and irritability are common. The most frequent causes of headaches in ambulatory patients are primary headaches (migraine and tension headaches). Lack of sleep, stress, symptoms of anxiety and depression, and abuse of analgesic drugs are the most common factors that contribute to the frequency of headaches. Magnesium deficiency is another factor, the role of which has been discussed in the frequency of primary headaches, in the development of neurotic disorders and depression. Clinical manifestations of magnesium deficiency itself usually include such nonspecific symptoms as fatigue, anxiety, irritability, numbness in the extremities, leg cramps, sleep disorders, etc.Magnesium deficiency is widespread among the population of developed countries, especially among women of reproductive age, often occurs during pregnancy, while taking oral contraceptives. Magnesium is involved in the regulation of the nervous system, neuromuscular transmission, cardiac activity, regulation of vascular tone, blood clotting and bone tissue metabolism. Magnesium deficiency is associated with diseases such as coronary heart disease, hypertension, type 2 diabetes, Alzheimer’s disease, migraine, osteoporosis, depression, neurotic disorders (panic disorder, generalized anxiety, various phobias), and fibromyalgia syndrome. Stress can lead to a decrease in magnesium levels in the body, and magnesium deficiency, in turn, reduces tolerance to stressful situations. Timely diagnosis and adequate treatment of magnesium deficiency and associated conditions represent important clinical challenges.The clinical case of a patient with neurotic disorder, headache and magnesium deficiency is presented, and the effectiveness of an interdisciplinary approach including an educational talk, adequate therapy for headache management, magnesium drug therapy and psychological methods is demonstrated. The role of magnesium deficiency in the development of various neurologic diseases is reviewed. The most effective magnesium compounds for therapy are discussed. Principles of diagnosis and treatment of patients with magnesium deficiency are presented.
25
Stein, Leah I., Christianne J. Lane, Marian E. Williams, Michael E. Dawson, José C. Polido, and Sharon A. Cermak. "Physiological and Behavioral Stress and Anxiety in Children with Autism Spectrum Disorders during Routine Oral Care." BioMed Research International 2014 (2014): 1–10. http://dx.doi.org/10.1155/2014/694876.
Full textAbstract:
Background. Children with autism spectrum disorders (ASD) commonly exhibit uncooperative behaviors which impede oral care. Previous studies have utilized dentist-report measures of uncooperative behaviors in children with ASD but none have utilized an objective measure of children’s behavior or a physiological measure of distress. This study investigated behavioral and physiological distress in children with ASD during routine oral care and examined factors associated with this distress.Methods. Participants were 44 children (n=22typical,n=22ASD) aged 6–12 receiving routine dental cleanings. Behavioral and physiological measures of stress and anxiety were collected during dental cleanings.Results. Children with ASD exhibited greater distress, compared to the typical group, on dentist-report and researcher-coded measures of overt distress behaviors and on physiological measures. Correlations between physiological and behavioral measures of distress were found in the ASD but not in the typical group. Behavioral distress was correlated with age in the typical group and with expressive communication ability and sensory processing difficulties in the ASD group; physiological distress was correlated with parent-report of anxiety in the typical group and sensory processing difficulties in the ASD group.Conclusions. Novel strategies may be required to decrease behavioral and physiological distress in children with ASD in the dental clinic.
26
Haralur, Satheesh B. "Clinical Strategies for Complete Denture Rehabilitation in a Patient with Parkinson Disease and Reduced Neuromuscular Control." Case Reports in Dentistry 2015 (2015): 1–5. http://dx.doi.org/10.1155/2015/352878.
Full textAbstract:
The dentist has a large role in geriatric health care for the ever increasing elder population with associated physical and neurological disorders. The Parkinson disease is progressive neurological disorder with resting tremor, bradykinesia, akinesia, and postural instability. The psychological components of disease include depression, anxiety, and cognitive deficiency. Poor oral hygiene, increased susceptibility for dental caries, and periodontal diseases predispose them to early edentulism. The number of Parkinson affected patients visiting dental clinic seeking complete denture is growing. This case report explains the steps involved in the complete denture rehabilitation of Parkinson patient. The effective prosthesis will help in alleviating functional, aesthetic, and psychological disabilities of the patient.
27
Jurgita, Andruškienė, Barsevičienė Šarūnė, Mažionienė Asta, and Virbalienė Akvilė. "Relations Among Poor Sleep, Anxiety and Depression Among the Students of Health Sciences." Applied Research In Health And Social Sciences: Interface And Interaction 14, no. 1 (December 1, 2017): 26–38. http://dx.doi.org/10.1515/arhss-2017-0003.
Full textAbstract:
AbstractThe research in the area of health sciences students’ sleep quality and mood disorders is lacking in Lithuania, as well as other European countries. The aim of this study was to compare prevalence of poor sleep, anxiety and depression among the students according to the study programmes and to assess the relations among poor sleep, depression and anxiety. The study sample consisted of 672 Klaipeda State University of Applied Sciences students (95.5% were female), from 18 to 46 years of age. Sleep quality was evaluated by Pittsburgh Sleep Quality Index, anxiety by Hospital Anxiety and Depression Scale, sociodemographic questions were used. The chi-square test or Fisher exact test was used to estimate association between categorical variables. P-values less than 0.05 were interpreted as statistically significant. Poor sleep was more prevalent among Beauty Therapy (26.4%, 95% CI 22.2-30.56) and Nursing (21.3%, 95% CI 17.42 – 25.17) students, as compared with persons studying in Oral Health programmes (14.8%, 95% CI 11.46 – 18.17), p<0.05. Depression mean score was higher in Beauty Therapy students (4.76), as compared to Oral Health (3.69) students, p<0.05. Beauty Therapy (9.99) or Physiotherapy students (8.24) had higher anxiety mean score, as compared to Oral Health students (7.14), p<0.05. Anxiety mean score was significantly higher (8.45) among the ones with disturbed sleep, as compared to normally sleeping students (5.86), p<0.001. Depression mean score (4.77) was higher among the students having disturbed sleep, as compared to the students which sleep was not disturbed (2.87), p<0.001. Poor sleep and anxiety were more prevalent among the students aged 20 years and older as compared to the students, aged 18 and 19 years. Second and third year students more often had poor sleep or anxiety as compared to the first-year students. Poor sleep and anxiety were more common among Beauty Therapy and Physiotherapy students than among Oral Health Students. Among the students who slept poorly, symptoms of anxiety and depression were statistically significantly more frequent than those students whose sleep was not disturbed. Depression and anxiety mean scores were statistically significantly higher among the students who had poor sleep, as compared to the ones who had normal sleep, in all age and year of studying groups.
28
Bogolepova, A. N., S. G. Burd, A. V. Lebedeva, and E. A. Kovalenko. "Experience with citicoline in patients with post-stroke cognitive impairment." Neurology, Neuropsychiatry, Psychosomatics 12, no. 4 (August 27, 2020): 43–48. http://dx.doi.org/10.14412/2074-2711-2020-4-43-48.
Full textAbstract:
Objective: to investigate the efficacy and safety of citicoline (Ceresil® Canon) in patients with post-stroke cognitive impairment.Patients and methods. Examinations were made in 33 patients aged 45 years and older who had experienced primary ischemic hemispheric stroke with complaints of a decline in memory or other cognitive functions. The cognitive status was assessed using the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA). The presence of anxiety-depressive spectrum disorders was determined on the Hospital Anxiety and Depression Scale. All the patients received citicoline (Ceresil® Canon) oral solution at a dose of 1000 mg/day for 3 months.Results and discussion. Citicoline administration showed a statistically significant reduction in the severity of cognitive impairment (p<0.001). The time course of positive changes in the cognitive status of patients was reflected by an increase in the median score on the MMSE from 26 [25; 27.5] to 28 [26.5; 29] and on MoCA from 23 [21; 25] to 25 [22; 26]. There was a decline in the number of patients with anxiety-depressive disorders. No adverse events or side effects were found in the patients.Conclusion. The findings suggest that citicoline (Ceresil® Canon) produced as an oral solution is well tolerated and improves cognitive functions and affective sphere in patients in the recovery period of ischemic stroke.
29
Nandini Prashanth Bhat, Sairoz, Divya C, Ashwija Shetty, Lydia Quadros, Hareesh Krishnan, and Pugazhandhi Bakthavatchalam. "Efficacy of Aconite and Ignatia as an anxiolytic- In vivo study." International Journal of Research in Pharmaceutical Sciences 12, no. 2 (May 25, 2021): 1484–89. http://dx.doi.org/10.26452/ijrps.v12i2.4719.
Full textAbstract:
Anxiety disorders are the most common form of psychiatric disorders and start at an early age. The homeopathic system of complementary treatment is increasingly used by the general population. Ultra-diluted Aconite and Ignatia are homeopathic medicines used by clinicians for the treatment of anxiety. The objective of this study is to test the efficacy of Aconite 12CH and Ignatia 12CH on experimental anxiety models of Wistar rats subjected to chronic unpredictable stress. 30 Wistar rats were divided into 5 groups of Control, Stress, Vehicle, Aconite and Ignatia group with 6 animals in each group. All the groups were subjected to chronic unpredictable stress except the control group. The last two groups were fed Aconite and Ignatia through oral gavage daily for 5 weeks. Following this, a behavioral and biochemical assessment was done. It was observed that the Aconite and Ignatia treated animals showed better weight gain, but the behavioral and biochemical assessment did not show any significant change. Hence it was inferred that ultra-diluted Aconite and Ignatia though an anxiolytic used clinically, did not decrease anxiety in Wistar rats which were subjected to chronic unpredictable stress.
30
Orengul, Abdurrahman Cahid, Mahmut Cem Tarakcioglu, Vahdet Gormez, Sumeyye Akkoyun, Aziz Zorlu, Nigar Aliyeva, Selcuk Uzuner, Yasin Caliskan, and Alperen Bikmazer. "Duration of Breastfeeding, Bottle-Feeding, and Parafunctional Oral Habits in Relation to Anxiety Disorders Among Children." Breastfeeding Medicine 14, no. 1 (February 2019): 57–62. http://dx.doi.org/10.1089/bfm.2018.0013.
Full text
31
Kisely, Steve, Emily Sawyer, Dan Siskind, and Ratilal Lalloo. "The oral health of people with anxiety and depressive disorders – a systematic review and meta-analysis." Journal of Affective Disorders 200 (August 2016): 119–32. http://dx.doi.org/10.1016/j.jad.2016.04.040.
Full text
32
Schierz, Oliver, Mike T. John, Daniel R. Reißmann, Mats Mehrstedt, and András Szentpétery. "Comparison of perceived oral health in patients with temporomandibular disorders and dental anxiety using oral health-related quality of life profiles." Quality of Life Research 17, no. 6 (June 4, 2008): 857–66. http://dx.doi.org/10.1007/s11136-008-9360-3.
Full text
33
Cherukupally, Karthik R., Kodjovi Kodjo, Oluwaseun Ogunsakin, Olaniyi Olayinka, and Patrice Fouron. "Comorbid Depressive and Anxiety Symptoms in a Patient with Myasthenia Gravis." Case Reports in Psychiatry 2020 (January 8, 2020): 1–3. http://dx.doi.org/10.1155/2020/8967818.
Full textAbstract:
Introduction. Myasthenia gravis (MG) is a chronic illness most commonly found in women under 40 years. The most common psychiatric comorbidities found in MG include depressive and anxiety disorders. Clinical Presentation. We describe a case of a 43-year-old African American female with MG who was brought in for shortness of breath. History included MG diagnosed twelve years prior to the current presentation and a history of seven intubations. The patient was admitted to the ICU and intubated. She endorsed poor sleep, easy fatigability, and feeling hopeless in the context of psychosocial stressors—being single, homeless, and unemployed. The patient was started on Zoloft 50 mg per oral daily for depression and Atarax 50 mg per oral three times a day for anxiety. The patient responded well to the treatment and was discharged on day 10 after the resolution of her symptoms with appropriate aftercare in place. Discussion. Depressive and anxiety symptoms usually develop as comorbidity during MG disease. Depressive and anxiety symptoms, besides motor symptoms, have a negative impact on the quality of life. Mental health must be a clinical focus during the treatment of somatic symptoms during MG.
34
Yadav, Nitesh, Pushpendra Soni, and Lavakesh Kumar Omray. "Formulation, Development and Evaluation of Fast Dissolving Oral Film of a Selective Serotonin-Reuptake Inhibitor (SSRIS) Escitalopram Oxalate." Journal of Drug Delivery and Therapeutics 10, no. 2 (March 15, 2020): 175–79. http://dx.doi.org/10.22270/jddt.v10i2.3938.
Full textAbstract:
The purpose of this research was to develop fast dissolving oral film of Escitalopram oxalate. Fast dissolving oral film offers a solution for paediatrics, geriatrics; psychiatric or mentally ill people and those have difficulty in swallowing tablets/capsules resulting in improved patient compliance. Selective serotonin reuptake inhibitors (SSRIs), which are broad spectrum antidepressants that are effective for major depressive disorder and several anxiety disorders. Escitalopram Oxalate is highly selective, more effective and better than other SSRIs. The prepared formulations were evaluated for Thickness, Weight uniformity, Folding Endurance, Percentage of Moisture Content, Drug Content Analysis, Disintegrating time and In vitro dissolution study. Stability studies were carried out with optimized formulation F5 which was stored for a period of one, two and three months at 40±2oC temperature and 75±5% relative humidity for a period 3 months. Thus it can be concluded that Escitalopram oxalate fast dissolving films could be commercially exploited for the treatment of panic disorder using Escitalopram oxalate with merits of faster onset of action, avoidance of extensive first pass metabolism, low dosage regimen, enhanced bioavailability and improved patient compliance.
Keywords: Escitalopram oxalate, Fast dissolving oral film, Evaluation
35
Kasper, S., S. M. Gastpar, W. E. Müller, H. P. Volz, H. J. Möller, A. Dienel, and S. Schläfke. "Efficacy and safety of silexan, a new, orally administered lavender oil preparation, in subthreshold anxiety disorder." European Psychiatry 26, S2 (March 2011): 160. http://dx.doi.org/10.1016/s0924-9338(11)71871-5.
Full textAbstract:
A number of studies has been performed recently on the efficacy and tolerability of silexan, a novel preparation from lavender oil for oral use, in the treatment of anxiety disorders and related conditions with particular attention to subthreshold generalized anxiety disorder (GAD). Three randomized, double-blind clinical trials were identified which investigated the efficacy of silexan in subsynromal anxiety disorder (vs. placebo; 10 weeks’ treatment), in GAD (vs. lorazepam; 6 weeks), and in restlessness and agitation (vs. placebo; 10 weeks) according to DSM-IV and ICD-10 criteria. One open-label pilot study assessed the potential of the medicinal product in neurasthenia, posttraumatic stress disorder and somatization disorder (6 weeks). All trials assessed the participants’ anxiety levels using the Hamilton Anxiety Scale (HAMA) or the State Trait Anxiety Inventory (STAI) as well as measures of co-morbidity and clinical global impressions. Across all trials 280 patients were exposed to silexan 80 mg/day, 37 were treated with lorazepam 0.5 mg/day and 192 received placebo. Average within group HAMA total scores at baseline ranged between 24.7 and 27.1 points. Patients treated with silexan showed average HAMA total score decreases by between 10.4 ± 7.1 and 12.0 ± 7.2 points at week 6 and by between 11.8 ± 7.7 and 16.0 ± 8.3 points at week 10. In subthreshold GAD silexan was significantly superior to placebo, with a mean value difference of at least 4 points (lower bound of 95% confidence interval (CI)) after 10 weeks. In GAD silexan and lorazepam showed comparable HAMA total score reductions (90% CI for mean value difference: -2.3; 2.8 points). The decrease of anxiety levels was accompanied by a reduction of restlessness and co-morbidity, and by improvements in general well-being. The anxiolytic effect of silexan is superior to placebo and comparable to lorazepam in subthreshold and threshold GAD, respectively. The medicinal product also improved associated symptoms like restlessness, disturbed sleep and somatic complaints, and had a beneficial influence on general well-being and quality of life. Silexan may offer interesting perspectives particularly in the treatment of subthreshold GAD.
36
Dokras, Anuja, David B. Sarwer, Kelly C. Allison, Lauren Milman, Penny M. Kris-Etherton, Allen R. Kunselman, Christy M. Stetter, et al. "Weight Loss and Lowering Androgens Predict Improvements in Health-Related Quality of Life in Women With PCOS." Journal of Clinical Endocrinology & Metabolism 101, no. 8 (August 1, 2016): 2966–74. http://dx.doi.org/10.1210/jc.2016-1896.
Full textAbstract:
Context: Polycystic ovary syndrome (PCOS) is associated with reduced health-related quality of life (HRQOL) and increased prevalence of depressive and anxiety disorders. The impact of PCOS-specific treatments on these co-morbidities is unclear. Objective: To assess the impact of weight loss and decreasing hyperandrogenism on HRQOL and mood and anxiety disorders in women with PCOS. Design/Setting/Participants: A secondary analysis of a randomized controlled trial (OWL-PCOS) of preconception treatment conducted at two academic centers in women (age, 18–40 years; body mass index, 27–42 kg/m2) with PCOS defined by Rotterdam criteria. Intervention: Continuous oral contraceptive pill (OCP) or intensive lifestyle intervention or the combination (Combined) for 16 weeks. Main Outcome Measure(s): Changes in HRQOL assessed by PCOSQ and SF-36 and prevalence of depression and anxiety disorder assessed by PRIME-MD PHQ. Results: The lowest scores were noted on the general health domain of the SF-36 and the weight and infertility domains on the PCOSQ. All three interventions resulted in significant improvement in the general health score on the SF-36. Both the OCP and Combined groups showed improvements in all domains of the PCOSQ (P < .01) compared to baseline scores. The Combined group had significant improvements in the weight, body hair, and infertility domains compared to a single treatment group (P < .05). In a linear regression model, change in weight correlated with improvements in the weight domain (P < .001) and physical well-being (P < .02), change in T correlated with improvements in the hair domain (P < .001), and change in both weight and T correlated with the infertility (P < .001) and menstrual domains (P < .05). Conclusions: Both weight loss and OCP use result in significant improvements in several physical and mental domains related to quality of life, depressive symptoms, and anxiety disorders, and combined therapies offer further benefits in overweight/obese women with PCOS.
37
Desmond, Hailey E., Clare Lindner, Jonathan P. Troost, Zack Held, Andrea Callaway, Gia J. Oh, Richard Lafayette, et al. "Association between Psychiatric Disorders and Glomerular Disease." Glomerular Diseases 1, no. 3 (July 8, 2021): 118–28. http://dx.doi.org/10.1159/000516359.
Full textAbstract:
<b><i>Introduction:</i></b> Patients with chronic health conditions, particularly chronic kidney disease, are at heightened risk for psychiatric disorders; yet, there are limited data on those with primary glomerular disease. <b><i>Methods:</i></b> This study included patients with glomerular disease enrolled in the kidney research network multisite patient registry. Registry data include encounter, diagnoses, medication, laboratory, and vital signs data extracted from participants’ electronic health records. ICD-9/10 diagnosis codes were used to identify a subset of psychiatric disorders focused on anxiety, mood, and behavioral disorders. Time-varying Cox proportional hazard models were used to analyze time from the onset of kidney disease to diagnosis of psychiatric disorder. Adjusted models retained significant covariates from the full list of potential confounders, including age, sex, race, ethnicity, time-varying treatment, the estimated glomerular filtration rate, and proteinuria (urine protein-to-creatinine ratio [UPCR]). Analogous models examined diagnosis of psychiatric disorder as a predictor of time to end-stage kidney disease (ESKD). <b><i>Results:</i></b> Data were available for 950 participants, with a median of 58 months of follow-up. 110 (12%) participants were diagnosed with psychiatric disorder during the follow-up. The estimated rate of psychiatric diagnosis after kidney disease was 14.7 cases per 1,000 person-years and was highest among those of adolescent age at the time of kidney disease diagnosis. Adjusted analyses found adolescent age (vs. adult, hazard ratio [HR] = 3.11, 95% confidence interval [CI] 1.87–5.17) and Asian race (vs. white, HR = 0.34, 95% CI 0.16–0.71) were associated with psychiatric diagnosis. A higher UPCR per 1 log unit (HR 1.13, 95% CI 1.01–1.27) and a higher total number of oral medications were associated with psychiatric disorder (<i>p</i> < 0.001). Psychiatric diagnosis was also associated with progression to ESKD (HR = 2.45, 95% CI 1.53–3.92) in adjusted models. <b><i>Discussion/Conclusion:</i></b> Psychiatric disorders were documented in approximately one-eighth of patients with glomerular disease and correlated with clinical disease characteristics such as age, race, proteinuria, and oral medication burden. These findings suggest mental health screening is warranted in patients of all ages with glomerular disease.
38
Cruz, José Henrique de Araújo, Lindoaldo Xavier Sousa, Bruno Firmino de Oliveira, Francisco Patrício de Andrade Júnior, Maria Angélica Satyro Gomes Alves, and Abrahão Alves de Oliveira Filho. "Disfunção temporomandibular: revisão sistematizada." ARCHIVES OF HEALTH INVESTIGATION 9, no. 6 (October 10, 2020): 570–75. http://dx.doi.org/10.21270/archi.v9i6.3011.
Full textAbstract:
Introdução: Disfunção Temporomandibular (DTM) é o termo para designar um quadro de desorganização neuromuscular identificada pela presença de cefaleias crônicas, sons na articulação temporomandibular, restrições dos movimentos mandibulares, hiperestesia e dor nos músculos da mastigação, da cabeça e do pescoço. Objetivo: realizar uma revisão de literatura sobre a DTM. Material e Método: foi feita uma seleção de artigos científicos a partir das bases de dados LILACS e SCIELO utilizando os descritores “Articulação Temporomandibular”, “Transtornos da Articulação Temporomandibular” e “Dor Facial”, usando como critérios de inclusão trabalhos brasileiros e inglês publicados em português e inglês no período de 2000 a 2018. Dos 798 artigos encontrados e delimitados pelos critérios inclusivos, foram selecionados 56 artigos como amostra, que apresentaram a temática elencada para a pesquisa e que foram discutidos nas seguintes sessões: a) Conceitos e epidemiologia; b) Etiologia; c) Sintomatologia; d) Diagnóstico; e) Tratamento. Conclusão: as causas da DTM são multifatoriais e seu diagnóstico deve ser minucioso. Observa-se a importância da anamnese para coleta de dados sintomatológicos da doença e o estudo de cada caso para melhor adequar a técnica de tratamento a ser utilizada. Há a necessidade de avaliações clínicas multidisciplinares nos indivíduos identificados com DTM para que o tratamento seja otimizado, minimizando a morbidade e diminuindo os custos do tratamento.
Descritores: Articulação Temporomandibular; Transtornos da Articulação Temporomandibular; Dor Facial.
Referências
Capellini VK, Souza GS, Faria CRS. Massage therapy in the management of myogenic TMD: a pilot study. J Appl Oral Sci. 2006;14(1):21-6.
Bastos LVW, Tesch RS, Denardin OV. Alterações cefalométricas presentes em crianças e adolescentes com desordens da ATM nas diferentes classificações sagitais de má oclusão. R Dental Press Ortodon Ortop Facial. 2008;13(2):40-8.
Menezes MS, Bussadori SK, Fernandes KPS, Gonzalez DAB. Correlação entre cefaleia e disfunção temporomandibular. Fisioterapia e Pesquisa. 2008,15(2):183-7.
Branco RS, Branco CS, Tesch RS, Rapoport A. Frequência de relatos de parafunções nos subgrupos diagnósticos de DTM de acordo com os critérios diagnósticos para pesquisa em disfunções temporomandibulares (RDC/TMD). R Dental Press Ortodon Ortop Facial. 2008;13(2):61-9.
Ritzel CH, Diefenthaeler F, Rodrigues AM, Guimarães ACS, Vaz MA. Temporo-mandibular joint dysfunction and trapezius muscle fatigability. Rev Bras Fisioter. 2007;11(5):333-9.
Kato MT, Kogawa EM, Santos CN, Conti PCR. Tens and low-level laser therapy in the management of temporo-mandibular disorders. J Appl Oral Sci. 2006;14(2):130-5.
Tomacheski DF, Barboza VL, Fernandes MR, Fernandes F. Disfunção têmporo-mandibular: estudo introdutório visando estruturação de prontuário odontológico. Publ UEPG Ci Biol Saúde. 2004;10(2):17-25.
Machado IM, Pialarissi PR, Minici TD, Rotondi J, Ferreira LP. Relação dos sintomas otológicos nas disfunções temporomandibulares. Arq Int Otorrinolaringol. 2010;14(3):274-9.
Venancio RA, Camparis CM, Lizarelli RFZ. Laser no Tratamento de Desordens Temporomandibulares. J. Bras. Oclusão, ATM, Dor Orofac. 2002;7:229-34.
Quinto CA. Classificação e tratamento das disfunções temporomandibulares: qual o papel do fonoaudió- logo no tratamento dessas disfunções? Rev CEFAC. 2000;2(2):15-22.
Piozzi R, Lopes FC. Desordens temporomandibulares: aspectos clínicos e guia para a odontologia e fisioterapia. J. Bras. Oclusão, ATM Dor Orofacial. 2002;2(5):43-7.
De Leeuw R. Dor orofacial: guia de avaliação, diagnóstico e tratamento 4ª ed. São Paulo: Quintessence;2010.
Carlsson GE, Magnusson T, Guimarães AS. Tratamento das disfunções temporomandibulares na clínica odontológica. 1ª. ed. São Paulo: Quintessence; 2006.
Köhler AA, Hugoson A, Magnusson T. Clinical signs indicative of temporomandibular disorders in adults: time trends and associated factors. Swed Dent J. 2013;37(1):1-11.
Scrivani SJ, Keith DA, Kaban LB. Temporomandibular disorders. New Engl J Med. 2008;59(25):693-705.
Gameiro GH, Silva Andrade A, Nouer DF, Ferraz de Arruda Veiga MC. How may stressful experiences contribute to the development of temporomandibular disorders? Clin Oral Investig. 2006;10(4):261-8.
Monteiro DR, Zuim PRJ, Pesqueira AA, Ribeiro PP, Garcia AR. Relationship between anxiety and chronic orofacial pain of Temporomandibular Disorder in a group of university students. J Prosthodont Res. 2011;55(3):154-8.
McMillan AS, Wong MCM, Lee LTK, Yeun RWK. Depression and diffuse physical symptoms in Southern Chinese with Temporomandibular Disorders. J Oral Rehabil. 2009;36(6):403-7.
Giannakopoulos NN, Keller L, Rammelsberg P, Kronmüller KT, Schmitter M. Anxiety and depression in patients with chronic temporomandibular pain and in controls. J Dent. 2010;38(5):369-376.
Fernandes G, Gonçalves DA, De Siqueira JT, Camparis CM. Painful temporomandibular disorders, self reported tinnitus, and depression are highly associated. Arq Neuropsiquiatr. 2013;71(12):943-7.
Mottaghi A, Razavi SM, Elham Zamani Pozveh E, Jahangirmoghaddam M. Assessment of the relationship between stress and temporomandibular joint disorder in female students before university entrance exam (Konkour exam). Dent Res J (Isfahan). 2011;8(Supl.1):76-9.
Pizolato RA, Freitas-Fernandes FS, Gavião MB. Anxiety/depression and orofacial myofacial disorders as factors associated with TMD in children. Braz Oral Res 2013;27(2):156-162.
Calixtre LB, Grüninger BLS, Chaves TC, Oliveira AB. Is there an association between anxiety/depression and Temporomandibular Disorders in college students? J Appl Oral Sci. 2014;22(1):15-21.
Winocur E, Gavish A, Finkelshtein T, Halachmi M, Gazit E. Oral habits among adolescent girls and their association with symptoms of temporomandibulardisorders. J Oral Rehabil. 2001;28(7):624-629.
Carvalho LPM, Piva MR, Santos TS, Ribeiro CF, Araújo CRF, Souza LB. Estadiamento clínico da disfunção temporomandibular: estudo de 30 casos. Odontol Clín-Cient. 2008;7(1):47-52.
Medeiros SP, Batista AUD, Forte FDS. Prevalência de sintomas de disfunção temporomandibular e hábitos parafuncionais em estudantes universitários. RGO 2011;59(2):201-208.
Valetic'-Peruzovic'm, Alajbeg I, Prpic'-Mehicic'g, Juros V, Illes D, Pelivan I. Acta Medica Croatica. 2008;62(2):179-187.
Gavish A, Halachmi M, Winocur E, Gazit E. Oral habits and their association with signs and symptoms of temporomandibular disorders in adolescent girls. J Oral Rehabil. 2000;27(1):22-32.
Thilander B, Rubio G, Pena L, Mayorga C. Prevalence of Temporomandibular Dysfunction and Its Association With Malocclusion in Children and Adolescents: An Epidemiologic Study Related to Specified Stages of Dental Development. Angle Orthod. 2002;72(2):146-154.
Paulino MR, Moreira VG, Lemos GA, Silva PLP, Bonan PRF, Batista AUD. Prevalência de sinais e sintomas de disfunção temporomandibular em estudantes pré-vestibulandos: associação de fatores emocionais, hábitos parafuncionais e impacto na qualidade de vida. Ciência & Saúde Coletiva. 2018;23(1):173-186.
Okeson, Jeffrey P. Etiologia e identifi cação dos distúrbios funcionais no sistema mastigatório. In:. Tratamento das desordens temporomandibulares e oclusão. 4. ed. São Paulo: Artes Médicas, 2000. p. 117-272.
Greene, Charles S. The etiology of temporomandibular disorders: implications for treatment. Journal of Orofacial Pain. 2001;15(2)93-105.
Bove SRV, Guimarães AS, Smith RL. Caracterização dos pacientes de um ambulatório de disfunção temporomandibular e dor orofacial. Rev Latino Enferm. 2005;13(5):686-91.
Detamore MS, Athanasiou KA. Structure and function of the temporomandibular joint disc: implications for tissue engineering. J Oral Maxillofac Surg. 2003;61(4):494-506.
Ramínez LM, Ballesterol LE, Sandoval GP. Otological symptoms among patients with temporimandibular joint disorders. Revista Médica de Chile. 2007;135(12):1582-90.
Felício CM, Melchior MDEO, Ferreira CL, Silva MA. Otologic symptoms of temporomandibular disorder and effect of orofacial myofunctional disorder and effect of orofacial myofunctional therapy. Cranio. 2008;26(2):118-25.
Bertoli, Elizangela de et al. Prevalence and impact of post-traumatic stress disorder symptoms in patients with masticatory muscle or temporomandibular joint pain: differences and similarities. Journal of Orofacial Pain, Carol Stream, v. 21, n. 2, p. 107-119, Spring 2007.
Reissmann, Daniel R. et al. Functional and psychosocial impact related to specifi c temporomandibular disorder diagnoses. Journal of Dentistry, Guildford, v. 35, n. 8, p. 643-650, Aug. 2007.
Aggarwal, Vishal R. et al. Psychosocial interventions for the management of chronic orofacial pain Psychosocial interventions for the management of chronic orofacial pain Psychosocial interventions for the management of chronic orofacial pain. Cochrane Database of Systematic Reviews, Oxford, v. 9, n. 11, CD008456, Nov. 2011.
Costa, Max Dória; Froes Junior, Gontran da Rocha Torres; SANTOS, Carlos Neanes. Avaliação de fatores oclusais em pacientes com disfunção temporomandibular. Dental Press Journal of Orthodontics, Maringá, v. 17, n. 6, p. 61-68, nov./dez. 2012.
Liao, Chun-Hui et al. The risk of temporomandibular disorder in patients with depression: a population-based cohort study. Community Dentistry and Oral Epidemiology, Copenhagen, v. 39, n. 6, p. 525-531, Dec. 2011.
Conti PCR. Behavioural changes and occlusal splints are effective in the management of masticatory myofascial pain: a short-term evaluation. Journal of Oral Rehabilitation. 2012;39(10):754-60.
John MT, Reissmann DR, Schierz O, Wassell RW. Oral health-related quality of life in patients with temporomandibular disorders. J Orofac Pain. 2007;21(1):46-54.
Barros VMM, Seraidarian PI, Côrtes MI, Paula LV. The impact of orofacial pain on the quality of life of patients with temporomandibular disorder. J Orofac Pain. 2009;23(1):28-37.
Schierz O, John MT, Reissmann DR, Mehrstedt M, Szentpétery A. Comparison of perceived oral health in patients with temporomandibular disorders and dental anxiety using oral health-related quality of life profiles. Qual Life Res. 2008;17(6):857-66.
Dahlström L, Carlsson GE. Temporomandibular disorders and oral health-related quality of life. A systematic review. Acta Odontol Scand. 2010;68(2):80-85.
Lemos GA, Paulino MR, Forte FDS, Beltrão RTS, Batista AUD. Influence of temporomandibular disorder presence and severity on oral health-related quality of life. Rev Dor. 2015;16(1):10-14.
Ballegaard V, Thede-Schmidt-Hansen P, Svensson P, Jensen R. Are headache and temporomandibular disorders related? A blinded study. Cephalalgia. 2008;28(8):832-41.
Plesh O, Noonan C, Buchwald DS, Goldberg J, Afari N. Temporomandibular disorder-type pain and migraine headache in women: A preliminary twin study. J Orofac Pain. 2012;26(2):91-8.
Melo GM, Barbosa JFS. Parafunção x DTM: a influência dos hábitos parafuncionais na etiologia das desordens temporomandibulares. POS. 2009; 1(1):43-8.
Guhur MLP, Alberto RN, Carniatto N. Influências biológicas, psicológicas e sociais do vestibular na adolescência. Roteiro. 2010;35(1):115-38.
Cuccia AM, Caradonna C, Caradonna D. Manual Therapy of the mandibular accessory ligaments for the management of temporomandibular joint disorders. JAOA. 2011;111(2):102-12.
Pasinato F, Souza JA, Corrêa ECR, Silva AMT. Temporomandibular disorder and generalized jointhypermobility: app lication of diagnostic criteria. Braz J Otorhinolaryngol. 2011;77(4):418-425.
Sabatke S, Bonotto D, Cunali PA. Disfunção têm poro-mandibular (DTM) e cefaleia: associação frequente. Migrâneas cefaleias. 2006,9(3):78-9.
Fikackova H, Dostalova L, Vosicka R, Peterova V, Navratil L, Lesak J. Arthralgia of the temporomandibular joint and low-lewel laser therapy. Photomed Laser Surg. 2006;21(1):522-7.
Catão MHCV, Oliveira PS, Costa RO, Carneiro VSM. Avaliação da eficácia do laser de baixa intensidade no tratamento das disfunções temporomandibular: estudo clínico randomizado. Rev CEFAC. 2013;15(6):1601-8.
39
Bazhora, Yana I. "APPLICATION OF COGNITIVE-BEHAVIORAL THERAPY IN PATIENTS WITH UNCONTROLLED BRONCHIAL ASTHMA DUE TO EXCESS BODY WEIGHT AND OBESITY." Wiadomości Lekarskie 73, no. 1 (January 2020): 134–38. http://dx.doi.org/10.36740/wlek202001126.
Full textAbstract:
The aim: The aim of our study was to determine the effect of CBT in patients with uncontrolled BA against the background of excess body weight and obesity. Materials and methods: By the study design there were examined 78 patients who had a primary diagnosis of uncontrolled BA. Results: The patients in the main group had significant positive dynamics regarding a number of AQLQ questionnaires, namely emotions, activity, overall quality of life (p≤0.05). These patients also had a positive dynamics in overcoming anxiety-depressive disorders, namely from 10.23 ± 0.81 points anxiety disorders scored 7.65 ± 0.98 points after CBT, and depressive changes – from 10.01 ± 0.79 points to 7.69 ± 0.67 points by the HADS scale (p≤0.05). Conclusions: The use of CBT has a positive effect on certain indices of the AQLQ questionnaire (p≤0.05) and has a positive effect on the psychological state of the patient, namely, it reduces the manifestations of anxiety and depression (p≤0.05) in patients with uncontrolled asthma as well as improves the course of uncontrolled asthma by a number of indices, namely reducing the frequency of use of short-acting β-2-agonists, nocturnal symptoms of asthma, the amount of oral and peroral steroids.
40
Bhat, Nandini Prashanth, Anjaneyulu Konuri, Huban Thomas, Vidya Monappa, Hareesh Krishnan, and Prasanna Lokadolalu Chandrachur. "Anxiolytic activity of ultra-diluted Aconitum napellus on Wistar rats." International Journal of High Dilution Research - ISSN 1982-6206 19, no. 3 (April 2, 2021): 40–49. http://dx.doi.org/10.51910/ijhdr.v19i3.1020.
Full textAbstract:
Background: Anxiety disorders are highly prevalent that affect millions of people worldwide. Homeopathic system is gaining popularity due to its efficacy in chronic diseases. Ultra-diluted Aconitum napellus is a homeopathic medicine used by clinicians for treatment of acute anxiety.
Aim: Objective of this study is to test the efficacy of Aconite on experimental anxiety models of Wistar rats. Methodology: 18 Female Wistar rats were divided into Control, Anxiety, and Anxiety + Aconite (ANX+ACO) groups. Acute stress was induced by restraining the rats for six hours daily for five days in Anxiety and ANX + ACO groups. After five days of stress, a single dose of Aconite 200cH was given to ANX + ACO group through oral gavage, whereas control and anxiety group rats were maintained with a normal diet. Following this, behavioral assessment was done. Results: It was observed that the Aconite treated group had more number of entries and also the percentage of time spent in the open arm was higher than the stressed anxiety group. Histological study of the brain tissue procured from all three groups was analyzed. Conclusion: It was inferred that ultra-diluted homeopathic Aconite has decreased anxiety in Wistar rats which were subjected to acute restrain stress.
41
Borgonetti, Vittoria, Francisco Les, Víctor López, and Nicoletta Galeotti. "Attenuation of Anxiety-Like Behavior by Helichrysum stoechas (L.) Moench Methanolic Extract through Up-Regulation of ERK Signaling Pathways in Noradrenergic Neurons." Pharmaceuticals 13, no. 12 (December 17, 2020): 472. http://dx.doi.org/10.3390/ph13120472.
Full textAbstract:
The long-term use of anxiolytic and antidepressant drugs can cause a plethora of side effects and the use of complementary and alternative medicine, which is generally considered safer than conventional medicine, is consistently increasing. Helichrysum stoechas (L.) Moench methanolic extract (HSE) has shown MAO-A inhibitory properties in previous studies. With the aim of obtaining innovative and safer therapies for mood disorders, this study investigated the potential activity of HSE in the management of anxiety- and depression-related symptoms. HSE showed dose-dependent (30–100 mg/kg p.o.) anxiolytic-like activity in the light dark box and marble burying tests, without any antidepressant-like activity, as shown by the results of the tail suspension test. Additionally, HSE did not have any effect on the modulation of pain, which highlights its selectivity in the control of anxiety-related behavior. At active doses, HSE did not produce any sedative effect or result in impaired motor coordination and memory functions. Western blotting experiments showed the ability of HSE to counteract the reduction in the phosphorylation of ERK44/42, to restore brain-derived neurotrophic factor (BDNF) expression and to return cyclic AMP response element binding (CREB) levels to basal levels in noradrenergic hippocampal neurons of mice exposed to an anxiety-related environment, which indicates a protective role against anxiety behavior. These results suggest that oral administration of HSE might represent an interesting opportunity for the management of anxiety disorders.
42
Rugh, J. D., B. J. Woods, and L. Dahlström. "Temporomandibular Disorders: Assessment of Psychological Factors." Advances in Dental Research 7, no. 2 (August 1993): 127–36. http://dx.doi.org/10.1177/08959374930070020301.
Full textAbstract:
Factors such as psychological stress, anxiety, depression, oral habits, and chronic pain behaviors have been found in subgroups of Temporomandibular Disorders (TMD) patients. This paper reviews the current status of diagnostic methods and instruments designed to identify various psychological factors. The authors offer the following general conclusions: Although the DSM-III-R has significant limitations, it is currently the most common gold standard with which other psychological instruments are compared. There are several specific assessment instruments, such as the Beck Depression Inventory and the Zung Self-Rating Depression Scale, which have been found to have acceptable sensitivity and specificity scores. In addition, certain simple screening questions may be cost-effective for the identification of psychological factors. Because of studies indicating that the dentists' recognition of psychological factors is inaccurate, a brief screening questionnaire may be useful in TMD patients. The literature does not support the routine use of the MMPI. A major conclusion of this review is that there are several psychological instruments available which have demonstrated reasonable validity through a blind comparison with a gold standard. There is need for further development and testing of brief screening instruments using clinical decision methods.
43
Rahman, Md Mahmudur, Md Tauhidul Islam Chowdhury, Mohammad Selim Shahi, and Md Jalal Uddin. "Demographic and Non-Motor Clinical Profiles of Parkinson’s Disease Patients attended at a Tertiary Care Hospital in Bangladesh." Journal of National Institute of Neurosciences Bangladesh 4, no. 2 (December 10, 2018): 123–28. http://dx.doi.org/10.3329/jninb.v4i2.38927.
Full textAbstract:
Background: Parkinson’s disease can be presented as non-motor clinical features.Objective: The purpose of the present study was to observe the demographic and non-motor clinical profiles of Parkinson’s disease patients.Methodology: This descriptive cross-sectional study was carried out in the Department of Neurology at Mymensingh Medical College, Mymensingh, Bangladesh from January 2009 to December 2010 for a period of two(02) years. PD patient presents with both motor and non-motor symptoms. NMS has variable presentations like sensory, autonomic, psychiatric and sleep disorder. Parkinson’s disease patients were diagnosed clinically. Each patient was assessed by a standard questionnaire, including sensory, autonomic, psychiatric and sleep disorder symptoms.Result: A total number of51 Parkinson’s disease patients were recruited for this study. Mean (±SD) age of male and female were 57.51±7.1 years and 60.00±10.2 years. Out of the 51 patients, 58.8% patients had sensory, 72.5% patients had autonomic, 47.1% patients had neuro-psychiatric and 66.7% patients had sleep disturbance symptoms. The most frequent sensory symptoms were akathisia 47.1%, diffuse pain 37.3%,and tightening sensation 27.5%. The most frequent autonomic symptoms were excessive sweating 54.9%, palpitation 35.3%, oral dryness 33.3%. The most frequentneuro-psychiatric symptoms were fatigue 56.8%, anxiety 45.1%, and depression 23.5%. The most frequent sleep disorders were insomnia 54.9%, day time sleepiness 11.8% and restless leg syndrome 9.8%.Conclusion: In conclusion elderly male rural people are commonly presented with PD presented with akathisia, diffuse pain, excessive sweating, palpitation, oral dryness, fatigue, anxiety and depressionJournal of National Institute of Neurosciences Bangladesh, 2018;4(2): 123-128
44
Atsü, Saadet Sağlam, Sibel Güner, Nilgün Palulu, Ali Can Bulut, and Işın Kürkçüoğlu. "Oral parafunctions, personality traits, anxiety and their association with signs and symptoms of temporomandibular disorders in the adolescents." African Health Sciences 19, no. 1 (April 23, 2019): 1801. http://dx.doi.org/10.4314/ahs.v19i1.57.
Full text
45
Katrivanou, A., M. Skokou, E. Pasmatzi, A. Monastirli, S. Beratis, P. Gourzis, and D. Tsambaos. "PW01-32 - A Prospective study of depression, anxiety and mood disorders in acne patients treated with oral isotretinoin." European Psychiatry 25 (2010): 1451. http://dx.doi.org/10.1016/s0924-9338(10)71434-6.
Full text
46
Kempińska, Urszula, and Mykola Rudenko. "'Hook - up' in the sexual culture of Polish and Ukrainian students - a communique of research." International Journal of Pedagogy, Innovation and New Technologies 5, no. 1 (June 30, 2018): 50–57. http://dx.doi.org/10.5604/01.3001.0012.2139.
Full textAbstract:
'Hook -ups'- emotionally uninvolved sexual encounters are becoming more and more rooted in popular culture, reflecting the changing social and sexual attitudes. Hook-up behavior may include a wide range of sexual activities such as kisses, oral sex and penetration. Hook-up raises the anxiety of many researchers due to many negative consequences, such as sexual violence, sexually transmitted diseases, emotional disorders and / or unplanned pregnancy. The aim of the study was to answer the question: how often do Polish and Ukrainian students take sexual relations with strangers?
47
Gentil, Lia, Helen-Maria Vasiliadis, Djamal Berbiche, and Michel Préville. "Impact of depression and anxiety disorders on adherence to oral hypoglycemics in older adults with diabetes mellitus in Canada." European Journal of Ageing 14, no. 2 (July 23, 2016): 111–21. http://dx.doi.org/10.1007/s10433-016-0390-3.
Full text
48
Mannucci, Carmen, Fabrizio Calapai, Luigi Cardia, Giuseppina Inferrera, Giovanni D’Arena, Martina Di Pietro, Michele Navarra, Sebastiano Gangemi, Elvira Ventura Spagnolo, and Gioacchino Calapai. "Clinical Pharmacology ofCitrus aurantiumandCitrus sinensisfor the Treatment of Anxiety." Evidence-Based Complementary and Alternative Medicine 2018 (December 2, 2018): 1–18. http://dx.doi.org/10.1155/2018/3624094.
Full textAbstract:
Objective. The aim of this review is to analyze preclinical and clinical studies investigating the anxiety effects ofCitrus aurantiumorCitrus sinensisessential oils (EOs).Design. The bibliographic research was made on the major scientific databases. Analysis included only articles written in English and published on peer-reviewed scientific journals describing preclinical experiments and clinical trials carried out to investigate the antianxiety effects ofCitrus aurantium or Citrus sinensisEOs on anxiety disorders. Clinical studies reporting the antianxiety effects of products containingCitrus aurantiumorCitrus sinensisEOs in combination with other active substances, including medicinal plants, were excluded. Nine clinical studies fulfilled the criteria adopted for analysis.Results. Data show thatCitrus aurantiumorCitrus sinensisEOs produce anxiolytic effects both in preclinical experiments and in different clinical conditions.Citrus aurantiumEO aromatherapy reduced anxiety level in the great part of stress conditions studied (subjects affected by chronic myeloid leukemia and preoperative patients) except for a sample of patients subjected to colonoscopy. Exposition toCitrus sinensisEO in clinical studies shows to be positive in reducing anxiety level in patients waiting for dental treatment as well as in healthy volunteers submitted to an anxiogenic situation.Conclusions. Overview of clinical trials conducted withCitrus aurantiumorCitrus sinensison people with anxiety showed that inhalation or oral administration ofCitrus aurantiumand inhalation ofCitrus sinensiscan exert beneficial effects on anxiety; however, because of incomplete accuracy in the reporting of methodology, further more complete clinical studies are warranted.
49
Caraiane, Aureliana, Andreea Szalontay, Luana Andreea Macovei, Aurelia Romila, Lucian Laurentiu Indrei, Mioara Decusara, and Tiberiu Tarc. "Oral-Facial Manifestations Caused by the Use of Psychotropic Medication in Psychiatric Patients." Revista de Chimie 69, no. 6 (July 15, 2018): 1581–84. http://dx.doi.org/10.37358/rc.18.6.6374.
Full textAbstract:
The development of psychotropic chemotherapy with widespread use in the psychiatric clinic for its anxiolytic, hypnotic, antidepressant, psychostimulant or psycho-destructive sedative effects has given rise to a new pathology secondary to increased abuse and accessibility. Their neurotropism is generally exerted on the central nervous system at the level of the complex meso-diencephalo-striate structures, influencing the elementary psychic functions, but also the activity of the whole organism through the neuro-humoral system. The clinical investigation of the patient must be interdisciplinary in nature, as human beings are characterized by a bio-psycho-social unit, in which the various biological and psychological components, influenced to a greater or lesser extent by the social environment, are involved in a special way, which gives an original personality to everyone. There are five fundamental axes, which are usually evaluated: thinking, memory, attention, emotion and behavior. A disorder in any of these axes, intense enough to interrupt the normal activity in more than one operating field over a sufficiently long period of time, is diagnosable as a mental disorder. There is an indication borrowed from internal medicine regarding the acute character (weeks), subacute character (months) and chronic character (years), which is attached to the diagnosis. A small part of the entire psychiatric population suffers from severe conditions, which involve intermittent episodes of severe disinhibition, aggressive behavior and self- or hetero-directed violence. In most cases, we talk about conditions such as depression or anxiety disorders (panic disorder, phobias, obsessive-compulsive disorder), which do not make him a social predator, although they cause enormous suffering to the individual. This study includes 67 patients with mental illness. While conducting the study, we took into account that the first contact with the patient is essential for the results of the anamnesis, oral examination, risk assessment and provisional treatment plan. In the 67 cases there were performed mycological analyses. It is necessary that dentists have certain knowledge of psychology and psychopathology, in order to understand the mechanism of psychopathological reactions and avoid them.
50
Bozovic, Djordje, Nedeljka Ivkovic, Maja Racic, and Sinisa Ristic. "Salivary cortisol responses to acute stress in students with myofascial pain." Srpski arhiv za celokupno lekarstvo 146, no. 1-2 (2018): 20–25. http://dx.doi.org/10.2298/sarh161221172b.
Full textAbstract:
Introduction/Objective. Temporomandibular disorders (TMD) are characterized by the appearance of musculoskeletal pain and dysfunction of the masticatory system. The aims of this study were to evaluate the salivary cortisol levels in students with chronic myofascial pain (MFP) related to TMD during oral exam, as well as to analyze the correlation between salivary cortisol levels, TMD-related MFP, the level of anxiety, depression symptoms, somatization, and perceived stress. Methods. The study included 60 university students, who were allocated either into the group of students with MFP (n = 30) or into the control group of healthy students (n = 30). The level of salivary cortisol was measured on the exam day and during the control day when the students had no exams. Depression symptoms, somatization, perceived stress and anxiety were evaluated according to Axis II RDC/TMD, Perceived Stress Scale and State?Trait Anxiety Inventory. Results. Levels of salivary cortisol were significantly higher in the group of students with MFP in all phases of measurements compared to the control group (p < 0.01). Students with MFP also showed significantly higher depression symptoms, somatization, and trait anxiety scores than the control group. No significant group differences were found on the scales measuring state anxiety and perceived stress. The level of salivary cortisol was found to be in correlation with depression symptoms, state anxiety, and perceived stress, but not with chronic pain, somatization, and trait anxiety in students with TMD. Conclusion. Salivary cortisol could be an important indicator of psychological distress in TMD.